GKIM
LGND icon

GW&K Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

GW&K Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78M Buy
246,883
+97,382
+65% +$22.9M 0.61% 42
2026
Q1 		$29.8M Buy
149,501
+32,069
+27% +$6.34M 0.26% 142
2025
Q4 		$22.2M Buy
117,432
+85,297
+265% +$16.4M 0.19% 193
2025
Q3 		$5.69M Sell
32,135
-1,296
-4% -$193K 0.05% 265
2025
Q2 		$3.8M Sell
33,431
-1,427
-4% -$153K 0.03% 278
2025
Q1 		$3.67M Sell
34,858
-326
-0.9% -$36.9K 0.03% 282
2024
Q4 		$3.77M Sell
35,184
-2,577
-7% -$291K 0.03% 290
2024
Q3 		$3.78M Sell
37,761
-1,257
-3% -$127K 0.03% 281
2024
Q2 		$3.29M Sell
39,018
-747
-2% -$59.4K 0.03% 286
2024
Q1 		$2.91M Sell
39,765
-15,570
-28% -$1.15M 0.03% 293
2023
Q4 		$3.95M Buy
55,335
+17,905
+48% +$1.06M 0.04% 276
2023
Q3 		$2.24M Sell
37,430
-678
-2% -$44.6K 0.02% 304
2023
Q2 		$2.75M Sell
38,108
-750
-2% -$56.3K 0.03% 301
2023
Q1 		$2.86M Buy
38,858
+8,764
+29% +$623K 0.03% 292
2022
Q4 		$2.01M Sell
30,094
-18,644
-38% -$1.21M 0.02% 307
2022
Q3 		$2.62M Sell
48,738
-5,219
-10% -$307K 0.03% 290
2022
Q2 		$3M Sell
53,957
-1,944
-3% -$110K 0.03% 278
2022
Q1 		$3.92M Buy
55,901
+15,008
+37% +$1.09M 0.04% 274
2021
Q4 		$3.94M Buy
+40,893
New +$3.78M 0.03% 282

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GW&K Investment Management's LGND Position: Q2 2026 in Review

GW&K Investment Management increased its Ligand Pharmaceuticals (LGND) stake by 65% in Q2 2026, buying an estimated $22.9M and bringing the position to 246,883 shares worth $78M. The position accounts for 0.61% of the portfolio, ranked #42.

GW&K Investment Management first reported a position in LGND in Q4 2021 and has held it in 19 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • GW&K Investment Management held 246,883 shares of Ligand Pharmaceuticals worth $78M as of Q2 2026.
  • GW&K Investment Management bought 97,382 Ligand Pharmaceuticals shares in Q2 2026, an estimated $22.9M.
  • Ligand Pharmaceuticals made up 0.61% of GW&K Investment Management's portfolio in Q2 2026, its #42 holding.
  • GW&K Investment Management first reported a position in Ligand Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.